UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April ~~March 16~~1, 2026

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its Charter)

Texas	001-41422	~~001-41422~~	26-1344466
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	~~(Commission File Number)~~	(IRS Employer Identification No.)
550 Reserve Street, Suite 360
Southlake, Texas			76092
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s Telephone Number, Including Area Code: 682 237-7781

550 Reserve Street, Suite 360
Southlake, Texas		76092
(Address of Principal Executive Offices)		(Zip Code)

~~n/a~~Registrant’s Telephone Number, Including Area Code: (682) 237-7781

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock HSCS The ~~Nasdaq~~NASDAQ Stock Market LLC Warrants HSCSW The ~~Nasdaq~~NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a)(b) On ~~March~~April 161, 2026, ~~HeartSciences~~Mark ~~Inc.~~Hilz, ~~(the~~Chief ~~“Company”)~~Operating ~~issued~~Officer, aCorporate ~~press~~Secretary ~~release~~and ~~providing~~member ~~information~~of ~~regarding~~ the ~~Company’s~~Board ~~financial~~of ~~and~~Directors ~~operating~~of ~~results~~HeartSciences ~~for~~Inc. (the “Company”) ~~quarter~~passed ~~ended~~away ~~January~~at ~~31,~~the ~~2026~~age of 67, ~~and~~following ~~other~~a ~~business~~period ~~updates~~of illness. ~~The~~Mr. ~~press~~Hilz ~~release~~served as isa ~~furnished~~member asof ~~Exhibit~~the ~~99.1~~Company’s toBoard ~~this~~of ~~Current~~Directors ~~Report~~since on2013 ~~Form~~and ~~8-K~~as ~~(this~~its ~~“Current~~Chief ~~Report”)~~Operating Officer and isCorporate ~~incorporated~~Secretary bysince ~~reference herein~~March 2022.

The ~~information~~Company ~~contained~~mourns inthe ~~Item 2.02~~ loss of ~~this Current Report and Exhibit 99~~Mr.1 toHilz, ~~this~~an ~~Current~~esteemed ~~Report~~colleague, ~~shall~~visionary ~~not be deemed to be “filed” for purposes of Section 18 of the Securities~~ and ~~Exchange Act of 1934~~friend, asand ~~amended~~extends ~~(the~~its ~~“Exchange~~sincere ~~Act”),~~condolences ~~or otherwise subject~~ to ~~the~~his ~~liabilities~~family ofand ~~that~~loved section, nor shall it be deemed incorporated by reference in any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filingones.

~~Item~~As ~~9.01~~the ~~Financial~~MyoVista ~~Statements~~Insights™ software platform has now been launched and ~~Exhibits~~the MyoVista® wavECG™ has been submitted for the U.S. Food and Drug Administration (“FDA”) clearance, the Company does not anticipate hiring a new Chief Operating Officer or replacing the role in the foreseeable future. The Company does not anticipate any changes to its business, operations or planned commercialization of the MyoVista Insights platform, including its MyoVista® wavECG™ device submission to the FDA originally submitted to the FDA in December 2025 for 510(k) premarket clearance, as a result of Mr. Hilz’s passing.

Exhibit No.		Description
99.1*		Press Release dated January 31, 2026
Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			HEARTSCIENCES INC.
	HeartSciences Inc.
Date:	March 16, 2026	By:	/s/ Andrew Simpson
Date: April 3, 2026	By:	/s/ Andrew Simpson
			Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors
	Name: Title:	Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors

Filing Compare · HeartSciences Inc.